318 related articles for article (PubMed ID: 20840765)
1. Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells--interplay of ErbB and IGF1 signalling through IGFBP3 regulation.
Worthington J; Bertani M; Chan HL; Gerrits B; Timms JF
BMC Cancer; 2010 Sep; 10():490. PubMed ID: 20840765
[TBL] [Abstract][Full Text] [Related]
2. Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells.
Worthington J; Spain G; Timms JF
Mol Cell Proteomics; 2017 Apr; 16(4):608-621. PubMed ID: 28174229
[TBL] [Abstract][Full Text] [Related]
3. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells.
Mackay A; Jones C; Dexter T; Silva RL; Bulmer K; Jones A; Simpson P; Harris RA; Jat PS; Neville AM; Reis LF; Lakhani SR; O'Hare MJ
Oncogene; 2003 May; 22(17):2680-8. PubMed ID: 12730682
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
5. Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins.
Teutschbein J; Haydn JM; Samans B; Krause M; Eilers M; Schartl M; Meierjohann S
BMC Cancer; 2010 Jul; 10():386. PubMed ID: 20663135
[TBL] [Abstract][Full Text] [Related]
6. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
[TBL] [Abstract][Full Text] [Related]
7. Presence of EGF growth factor ligands and their effects on cultured rat conjunctival goblet cell proliferation.
Gu J; Chen L; Shatos MA; Rios JD; Gulati A; Hodges RR; Dartt DA
Exp Eye Res; 2008 Feb; 86(2):322-34. PubMed ID: 18155194
[TBL] [Abstract][Full Text] [Related]
8. Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network.
Weingaertner IR; Koutnik S; Ammer H
PLoS One; 2013; 8(1):e53510. PubMed ID: 23308242
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
11. ERBB2 overexpression triggers transient high mechanoactivity of breast tumor cells.
Martin M; Müller K; Cadenas C; Hermes M; Zink M; Hengstler JG; Käs JA
Cytoskeleton (Hoboken); 2012 May; 69(5):267-77. PubMed ID: 22407943
[TBL] [Abstract][Full Text] [Related]
12. Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
Wells V; Mallucci L
Breast Cancer Res; 2009; 11(1):R2. PubMed ID: 19133120
[TBL] [Abstract][Full Text] [Related]
13. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
Huang X; Gao L; Wang S; Lee CK; Ordentlich P; Liu B
Cancer Res; 2009 Nov; 69(21):8403-11. PubMed ID: 19826038
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
15. Involvement of connective tissue growth factor (CTGF) in insulin-like growth factor-I (IGF1) stimulation of proliferation of a bovine mammary epithelial cell line.
Zhou Y; Capuco AV; Jiang H
Domest Anim Endocrinol; 2008 Aug; 35(2):180-9. PubMed ID: 18586434
[TBL] [Abstract][Full Text] [Related]
16. Estradiol, progesterone, and transforming growth factor alpha regulate insulin-like growth factor binding protein-3 (IGFBP3) expression in mouse endometrial cells.
Maekawa T; Takeuchi S; Kanayama M; Takahashi S
Zoolog Sci; 2009 Feb; 26(2):131-8. PubMed ID: 19341330
[TBL] [Abstract][Full Text] [Related]
17. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
18. Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression.
White SL; Gharbi S; Bertani MF; Chan HL; Waterfield MD; Timms JF
Br J Cancer; 2004 Jan; 90(1):173-81. PubMed ID: 14710226
[TBL] [Abstract][Full Text] [Related]
19. Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands.
O-charoenrat P; Rhys-Evans P; Court WJ; Box GM; Eccles SA
Clin Exp Metastasis; 1999; 17(7):631-9. PubMed ID: 10845563
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of ERBB family mRNA expression in breast carcinomas.
Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
